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Determination of triapine, a ribonucleotide
reductase inhibitor, in human plasma by liquid
chromatography tandem mass spectrometry
Ye Feng , Charles A. Kunos and Yan Xu
Introduction
Ribonucleotide reductase (RNR) is an essential enzyme for cell
division as well as tumor growth (Finch et al., 1999), which not
only catalyzes the conserved reduction of ribonucleotides to de-
oxyribonucleotides, but also regulates the total rate of DNA syn-
thesis to maintain a constant ratio of DNA to cell mass during
cell proliferation and DNA repair (Jordan and Reichard, 1998;
Shao et al., 2006; Xu et al., 2008). There are two RNR isoforms
in human (two dimers of M1–M2 subunits, or two dimers of
M1–M2b subunits), and the catalytic function of the enzyme re-
lies on the essential iron-tyrosyl radical center in M2 or M2b sub-
units (Jordan and Reichard, 1998). Hence, it is a prime target for
the development of chemotherapeutic agents.
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone,
or 3-AP; Fig. 1A) is ametal-ion chelator and an experimental antican-
cer agent, which can disrupt the catalytic iron-tyrosyl radical center
in M2 or M2b subunit of RNR via the formation of triapine–Fe(III)
complex (Kowol et al., 2009). Compared with hydroxyurea (HU),
the only RNR-inhibitor drug currently used in chemotherapy,
triapine is 1000-foldmore potent for inhibition of RNR activity (Finch
et al., 1999). Studies have shown that triapine has a broader-
spectrum antitumor activity and can signiﬁcantly decrease RNR ac-
tivity in a variety of cancer cell lines including leukemia, nonsmall-
cell lung cancer, renal cancer and melanoma, and enhances
radiation-mediated cytotoxicity in cervical and colon cancers (Alvero
et al., 2006; Finch et al., 1999, 2000; Giles et al., 2003; Kuo et al., 2003;
Li et al., 2001). These promising pre-clinical studies have prompted a
large number of clinical trials. To date, there have been 36
clinical trials of triapine worldwide for various cancers at
various stages of studies (http://www.clinicaltrials.gov/ct2/results?
term=triapine&Search=Search, accessed 14 December 2014). At
the Case Comprehensive Cancer Center, the triapine studies have
been focused on the investigation of sensitizing potential of triapine
on radiation therapy of cervical and vaginal cancers (Kunos et al.,
2009, 2010a, 2010b, 2013).
Despite the therapeutic signiﬁcance of triapine, there is no
validated analytical method published for quantitation of
triapine in human biological samples. Several LC-UV assays have
been described for the measurement of triapine in clinical stud-
ies (Mortazavi et al., 2013; Murren et al., 2003; Yee et al., 2006);
however, when adopted, they often produced irreproducible re-
sults and were hindered by poor selectivity and inadequate
limits of quantitation. Our recent study revealed that factors in-
cluding solution pH, metal ions, other competing chelators and
buffer composition can affect the reproducibility of an LC-UV
method by inﬂuencing triapine complexation reaction, and the
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optimization of these factors is critical in the chromatography
method development (Feng et al., 2014).
In this work, we have developed and validated a reliable and se-
lective LC-MS/MS method based on our recent ﬁndings (Feng et al.,
2014) with adequate lower limit of quantitation (LLOQ) for determi-
nation of triapine in human plasma samples. Plasma samples were
prepared by direct protein precipitation with acetonitrile. The
method developed has been applied to the measurement of
triapine in patient samples obtained from a phase I clinical trial.
Experimental
Chemicals and materials
Triapine was provided by Vion Pharmaceuticals (New Haven, CT, USA)
and used as the chemical standard for this work. 2 [(3 Fluoro 2
pyridinyl)methylene] hydrazinecarbothioamide (NSC 266749 or CAS
31181 41 6) was obtained from the Developmental Therapeutics Pro
gram of the National Cancer Institute at the National Institutes of Health
(Bethesda, MD, USA) and used as the internal standard (IS). HPLC grade
methanol, ethylenediaminetetraacetic acid disodium salt (EDTA), and
ammonium hydroxide were purchased from Sigma Aldrich (St Louis,
MO, USA). Ammonium bicarbonate was from EMD Chemicals
(Darmstadt, Germany). Deionized water was obtained from a Barnstead
Model 7148 Nanopure® ultrapure water system (Thermo Scientiﬁc,
Asheville, NC, USA). Six lots of human blank plasma (EDTA treated), six
lots of human blank sera, and pooled human blank plasma were pur
chased from Innovative Research (Novi, MI, USA).
Preparation of stock and standard solutions
The stock solutions of triapine (1.00 mg/mL) and NSC 266749
(1.00 mg/mL) were prepared individually by dissolving appropriate
amount of each chemical in a known volume of methanol, and were kept
at20°C before use. The dilution solution which was prepared for dilution
of the stock solutions to working standard solutions contained 25.0%
acetonitrile and 75.0% ammonium bicarbonate EDTA (10.0 mM NH4HCO3
and 1.00 mM EDTA, pH 8.50) buffer (v/v). The working solutions of triapine
(1.00 μg/mL) and NSC 266749 (1.00 μg/mL) were freshly prepared by serial
dilution of each stock solution with the dilution solution.
Triapine standard solutions (5.00, 10.0, 15.0, 20.0, 50.0, 100, 150,
200, 500, 800 and 1.00 × 103 ng/mL) and NSC 266749 internal stan
dard solution (100 ng/mL) were prepared individually by serial dilution
of the working solutions of triapine (1.00 μg/mL) and NSC 266749
(1.00 μg/mL) with the dilution solution. These standard solutions were
used for the preparation of triapine plasma calibrators and quality
controls (QCs).
Preparation of triapine plasma calibrators, QCs and patients’
samples
Triapine plasma calibrators (0.250, 0.500, 1.00, 2.50, 5.00, 10.0, 25.0 and
50.0 ng/mL) and plasma quality controls (i.e. low , medium , high and
dilution QCs 0.750, 7.50, 40.0 and 400 ng/mL) were prepared individu
ally by mixing 200 μL of pooled blank human plasma and 10.0 μL of the
corresponding triapine standard solution, which was 20 times the cali
brator concentration. Patient plasma samples were prepared by mixing
200 μL of each patient’s plasma with 10.0 μL of the dilution solution to
match the sample matrix with those of the plasma calibrators and QCs.
Single blank plasma (or triapine plasma zero calibrator) was prepared
by mixing 200 μL of pooled blank human plasma with 10.0 μL of the di
lution solution. Double blank plasma (containing neither triapine nor the
IS) was prepared by mixing 200 μL of pooled blank human plasma with
20.0 μL of the dilution solution.
Prior to sample deproteinization, 10.0 μL of the IS solution (100 ng/mL)
was added to each of the above plasma samples (e.g. calibrators includ
ing zero calibrator, QCs and patient samples) except double blank
plasma and mixed well.
Deproteinization of plasma samples
Each plasma sample was mixed with 880 μL of acetonitrile (at a ratio of 4
to 1) and vortexed for 30 s. Following by centrifugation at 15,000 × g for
10 min, the supernatant was pipetted into a 1.5 mL microcentrifuge tube
and dried in a TurboVap® LV evaporator (Caliper Life Sciences,
Hopkinton, MA, USA) at 30°C under nitrogen gas. The resulting residue
was reconstituted in 110 μL of the dilution solution for LC MS/MS
analysis.
Instrumentation
The LC MS/MS instrumentation system used consisted of a Shimadzu
SIL 20AC autosampler (Shimadzu, Columbia, MD, USA), a Shimadzu
LC 20AD HPLC unit with a Waters Xbridge Shield RP18 column
(3.5 μm; 2.1 × 50 mm) and a mobile phase containing methanol and
10.0 mM ammonium bicarbonate (pH 8.50) at a ratio of 25:75 (v/v)
and an AB Sciex API 3200 turbo ionspray® triple quadrupole tandem
mass spectrometer (AB Sciex, Foster City, CA, USA). The system was
controlled by AB Sciex Analyst® (version 1.5.1) software.
The API 3200 tandem mass spectrometer was operated under the
positive turbo ionspray ionization mode and was tuned by a mixture of
500 ng/mL tiapine and 500 ng/mL the IS in 50% methanol and 50% am
monium bicarbonate (10.0 mM, pH 8.50) for both compound dependent
and source dependent parameters. The multiple reaction monitoring
(MRM) data were acquired with the following mass transitions:
m/z 196 > 121 for triapine, and m/z 199 > 124 for the IS. The optimized
instrument settings were as follows: curtain gas at 40; collision assisted
dissociation gas at 8; ionization voltage at 4500 V; source temperature
at 700; sheath gas at 50; desolvation gas at 40; desolvation potential
at 40; entrance potential at 4; collision energy at 23; collision cell exit
potential at 2; and resolution at unit.
The separation of triapine and the IS was accomplished by isocratic
elution with the mobile phase at a ﬂow rate of 0.300 mL/min. Prior to ini
tial sample analysis, the column was equilibrated with the mobile phase
at the ﬂow rate for at least 30 min. During each run, 10.0 μL of
reconstituted sample was injected into the system by the autosampler
set at 4.0°C. The two position switch valve on the API 3200 tandem
mass spectrometer was programmed to switch to the waste for the ﬁrst
1.2 min and then switch to the mass spectrometer. Quantitation of
triapine was carried out by the MRM mode of the tandem mass spec
trometer, and the total instrument run time for each sample analysis
was 4 min.
Method validation
The LC MS/MS method developed was validated in human plasma
according to the US Food and Drug Administration (2001) guidance for
industry on bioanalytical method validation and the white paper of the
2006 bioanalytical method validation workshop (Bansal and DeStefano,
Figure 1. The chemical structures of triapine and NSC 266749 (IS).
1381
2007) in terms of selectivity, LLOQ, recovery, matrix effect, linear re
sponse range, accuracy and precision, as well as stability for both
short term sample processing and long term sample storage.
Selectivity and LLOQ
The selectivity of this method was evaluated by observing any interfernts
at the same retention times and mass transitions of the analyte and the
IS in six individual blank plasma and pooled blank plasma matrices, as
well as in the pre dosed plasma from patients. The LLOQ of the method
was deﬁned as the lowest concentration of triapine plasma calibrator of
the calibration curve with accuracy and precision ≤±20 and 20%, which
was validated in six individual plasma, and pooled plasma matrices.
Matrix factor and recovery
The absolute matrix factor (MF) of triapine (or the IS) was determined by
the mean peak area of triapine (or the IS) at a speciﬁed concentration in
the deproteinized plasma matrix over that of triapine (or the IS) at the
concentration in the mobile phase. The IS normalized MF was deter
mined by the absolute MF of triapine over that of the IS. For this study,
triapine QCs at two concentrations (0.750 and 40.0 ng/mL) with a ﬁxed
concentration of the IS (5.00 ng/mL) were prepared in six individual
deproteinized plasma matrices and in the mobile phase.
The absolute recovery of triapine (or the IS) was determined by the
mean peak area of triapine (or the IS) at a speciﬁc concentration in
plasma matrix over the mean peak area of triapine (or the IS) at the con
centration in the deproteinized plasma matrix multiplied by 100%. The IS
normalized recovery was determined by the absolute recovery of
triapine over that of the IS multiplying by 100%. For this study, triapine
QCs at three concentrations (0.750, 7.50 and 40.0 ng/mL) with a ﬁxed
concentration of the IS (5.00 ng/mL) were prepared in the pooled human
plasma and the deproteinized pooled human plasma.
Calibration curve
The triapine calibration curve in human plasma was established using
double blank (plasma matrix with neither triapine nor the IS), single
blank (plasma matrix with only the IS) and eight nonzero plasma calibra
tors at the concentrations 0.250, 0.500, 1.00, 2.50, 5.00, 10.0, 25.0 and
50.0 ng/mL with the IS at the concentration 5.00 ng/mL. The peak area
ratios of triapine to the IS (y) were plotted against triapine calibrator con
centrations (x) with 1/x weighting.
Accuracy, precision and dilution study
Accuracy was expressed as percentage relative error (RE) and precision
as the coefﬁcient of variation (CV). In this work, the inter assay preci
sion and accuracy were assessed by ﬁve parallel analyses of ﬁve iden
tical QC samples at each of four QC concentrations (0.750, 7.50, 40.0
and 400 ng/mL). The intra assay precision and accuracy were assessed
by ﬁve replicate analyses of each QC samples. The above studies also
included the dilution study where the dilution QCs (400 ng/mL) were
prepared and analyzed after 10 fold dilution by the pooled human
blank plasma.
Stability study
The stability of triapine was investigated using stock and working solu
tions (1.00 mg/mL and 1.00 μg/mL) and plasma low and high QCs
(0.750 and 40.0 ng/mL), and the stability of NSC 266749 was also deter
mined separately using NSC 266749 standard solution (100 ng/mL) and
plasma sample containing 5.00 ng/mL of NSC 266749. In the NSC
266749 stability studies, triapine was used as the IS.
Stabilities of triapine stock and working solutions, triapine plasma
QCs, NSC 266749 standard solution and plasma samples were assessed
during short term (6 and 24 h) storage, standing on the bench top at
23°C and in the autosampler at 4°C (post preparative); during three
freeze thaw cycles (where the samples were frozen at 20°C for at least
24 h and thawed at room temperature, 23°C, unassisted); and during
long term storage (30 days) at 20°C. The stabilities of triapine and
NSC 266749 were determined by comparing the mean peak area ratios
of analyte to IS in the test sample with those of freshly prepared samples,
and expressed as percentages. For this study, all experiments were done
in ﬁve replicates.
Method application
The LC MS/MS method developed was tested for the measurement of
triapine in patient plasma samples collected from a previous phase I
Figure 2. The mass spectra of triapine and the IS. The experimental conditions were described in the ‘Instrumentation’ section under the
‘Experimental’.
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to preserve triapine from complexation. In this work, a dilution
solution containing 25.0% acetonitrile and 75.0% ammonium
bicarbonate–EDTA buffer (10.0 mM NH4HCO3 and 1.00 mM EDTA,
pH 8.50) was used for preparation of triapine working solution
from its stock in methanol, as well as triapine standards from
the working solution. It is also worth noting that triapine work-
ing and standard solutions prepared in Ultrapure HPLC-grade
bottled water from Fisher Scientiﬁc (Fair Lawn, NJ, USA) could
also give reproducible analytical signal if it was not contami-
nated by metal ions.
Plasma samples vs serum samples
Because EDTA can preserve triapine from complexation with
metal ions, a comparison study was conducted on the absolute
recovery and matrix effect of triapine from EDTA-treated human
plasma and serum samples using two types of preparation
methods, protein precipitation and liquid–liquid extraction. In
this work, triapine plasma and serum samples (at 7.50 ng/mL)
were prepared by spiking triapine standard solution in six lots
of human blank plasma and six lots of human blank serum.
These samples were prepared by protein precipitation with ace-
tonitrile and methanol, as well as liquid–liquid extraction with
acetyl acetate. As shown in Fig. 4, the absolute recoveries of
triapine were consistently higher from EDTA-treated plasma ma-
trices (67–91%) than those from serum matrices (24–69%) by
both types of sample preparation methods, and the absolute
matrix factors were much closer to unity for plasma samples
(0.750–0.800) than those of serum samples (0.120–0.200). Fur-
thermore, protein precipitation with 4 volumes of acetonitrile
produced greater recovery for triapine and comparable matrix
factor among the sample preparation methods. Therefore,
EDTA-treated plasma samples and protein precipitation by ace-
tonitrile were used for the method development and sample
preparation in the subsequent work. For clinical study of
triapine, EDTA-treated tubes are highly recommended for blood
collection.
Selectivity and LLOQ
The LC-MS/MS method developed was highly selective. As illus-
trated in Fig. 3(A), there were no detectable interferents ob-
served at the retention times and mass transitions of triapine
and the IS from six individual plasma and the pooled plasma ma-
trices, as well as the pre-dosed plasma from patients in a phase I
clinical trial (Kunos et al., 2010a, 2010b).
The LLOQ of the method for quantitation of tripaine in human
plasma was 0.250 ng/mL, which had signal-to-noise ratio of 23.5
Fig. 3B). Table 1 summarized the accuracy and precision of the
Table 1. Accuracy and precision of triapine at lower limit of
quantitation (LLOQ) in six lots of human plasmas (n = 5)
Plasma
matrix
Nominal
[triapine]
(ng/mL)
Measured
[triapine]
(ng/mL)
SD
(ng/mL)
Precision
(CV, %)a
Accuracy
(RE, %)b
Lot 1 0.250 0.225 0.004 2 10
Lot 2 0.250 0.26 0.02 8 4
Lot 3 0.250 0.26 0.01 4 4
Lot 4 0.250 0.248 0.007 3 1
Lot 5 0.250 0.261 0.007 3 4
Lot 6 0.250 0.250 0.008 3 0
Mean
(6 lots)
0.250 0.250 0.004 2 0
aCV = (standard deviation/mean) × 100%.
bRE = [(measured – nominal)/nominal] × 100%.
Table 2. Matrix effect of triapine in six individual lots of blank human plasma (n = 5)
Plasma
matrix
[Triapine]
(ng/mL)
PATriapine
a in
extracted plasma
± SD (×103)
PATriapine in
mobile phase
± SD (×103)
MFTriapine
b
± SDc
PAIS
d in
extracted plasma
± SD (×103)
PAIS in
mobile phase
± SD (×103)
MFIS
e
± SD
IS normalized
MFf ± SD
Lot 1 0.750 4.9 ± 0.4 6.4 ± 0.2 0.77 ± 0.07 22 ± 2 27.6 ± 0.5 0.80 ± 0.07 1.0 ± 0.1
40.0 265 ± 5 362 ± 2 0.73 ± 0.01 21.8 ± 0.8 28.3 ± 0.3 0.77 ± 0.03 0.95 ± 0.04
Lot 2 0.750 5.0 ± 0.3 6.4 ± 0.2 0.78 ± 0.05 22 ± 1 27.6 ± 0.5 0.80 ± 0.04 0.98 ± 0.08
40.0 2.7 × 102 ± 1 × 101 362 ± 2 0.75 ± 0.03 21.5 ± 0.7 28.3 ± 0.3 0.76 ± 0.03 0.99 ± 0.06
Lot 3 0.750 4.5 ± 0.2 6.4 ± 0.2 0.70 ± 0.04 21 ± 1 27.6 ± 0.5 0.76 ± 0.04 0.92 ± 0.07
40.0 243 ± 6 362 ± 2 0.67 ± 0.02 19.9 ± 0.5 28.3 ± 0.3 0.70 ± 0.02 0.96 ± 0.04
Lot 4 0.750 4.4 ± 0.3 6.4 ± 0.2 0.69 ± 0.05 20 ± 2 27.6 ± 0.5 0.72 ± 0.07 1.0 ± 0.1
40.0 206 ± 8 362 ± 2 0.57 ± 0.02 18 ± 1 28.3 ± 0.3 0.64 ± 0.04 0.89 ± 0.06
Lot 5 0.750 4.7 ± 0.2 6.4 ± 0.2 0.73 ± 0.04 19 ± 1 27.6 ± 0.5 0.69 ± 0.04 1.06 ± 0.08
40.0 2.4 × 102 ± 3 × 101 362 ± 2 0.66 ± 0.08 19 ± 2 28.3 ± 0.3 0.67 ± 0.07 1.0 ± 0.1
Lot 6 0.750 4.5 ± 0.2 6.4 ± 0.2 0.70 ± 0.04 19.6 ± 0.9 27.6 ± 0.5 0.71 ± 0.04 0.99 ± 0.08
40.0 2.3 × 102 ± 1 × 101 362 ± 2 0.64 ± 0.03 19.6 ± 0.2 28.3 ± 0.3 0.69 ± 0.01 0.93 ± 0.05
aPATriapine = mean peak area of triapine.
bMFTriapine = (PATriapine in extracted plasma matrix)/(PATriapine in mobile phase).
cy (±sy) = [a(±sa)/b(±sb)], sy = y × √[(sa/a)
2 + (sb/b)
2].
dPAIS = mean peak area of IS.
eMFIS = (PAIS in extracted plasma matrix)/(PAIS in mobile phase).
fIS normalized MF = MFTriapine/MFIS.
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method at LLOQ. By ﬁve replicate measurements of each plasma
matrix from six lots, the accuracy and precision were ≤±10 and
≤8%, respectively. These values were lower than those of the in-
dustry limits recommended by US Food and Drug Administra-
tion (≤±20 and ≤20%), which implied that the actual LLOQ of
the method could be <0.250 ng/mL if it was validated when
needed.
Matrix effect and recovery
Matrix effect was assessed by the MF using six independent lots
of human plasmas. As shown in Table 2, the absolute MFs of
triapine and the IS were 0.57–0.78 and 0.64–0.80, respectively,
and the IS normalized MFs were near unity (0.92–1.06). Hence,
the matrix effect of human plasma on the analytical signals
could be effectively corrected by the use of the IS.
The recovery data of triapine in pooled human plasma is
shown in Table 3. The absolute recoveries of triapine and the
IS were 89–93 and 88–89%, respectively, and the IS normalized
recovery was 101–104%. These results indicated that the protein
precipitation procedure was sufﬁcient to recover the analyte and
the IS from human plasma.
Linearity
The linear regression equation obtained from six batches over
3 days was y = 0.373(±0.012)x  0.00107(±0.00034) over the
range 0.250–50.0 ng/mL with individual correlation coefﬁ-
cients >0.999. The accuracy and precision of individual
plasma calibrators as summarized in Table 4 were ≤±6 and
≤8%, respectively.
Accuracy, precision and dilution integrity
As shown in Table 5, the accuracy and precision were ≤±8 and
≤5% for the intra-assay study and ≤±7 and ≤4% for the inter-
assay study, indicating the method developed was accurate
and precise. In this study, dilution QC (400 ng/mL) was in-
cluded because some of the patient plasma samples had
triapine concentrations beyond the upper limit of quantitation
(50.0 ng/mL) of the method. The accuracy and precision data
of the dilution QC (≤±2 and ≤ 0.5% for the intra-assay study
and ≤±7 and ≤ 1% for the inter-assay study) indicated that
the integrity of plasma sample could be preserved after sam-
ple dilution.
Table 3. Recovery of triapine in pooled human plasma (n = 5)
[Triapine]
(ng/mL)
PATriapine
a
in plasma
± SD (×103)
PATriapine in
extracted plasma
± SD (×103)
RecoveryTriapine
b
± SD (%)
PAIS
c in
plasma
± SD (×103)
PAIS in
extracted plasma
± SD (×103)
RecoveryIS
d
± SD (%)
IS normalized
recoverye
± SD (%)
0.750 3.2 ± 0.2 3.6 ± 0.1 89 ± 6 13.6 ± 0.7 15.5 ± 0.4 88 ± 5 101 ± 9
7.50 37.8 ± 0.8 41.5 ± 0.6 91 ± 2 13.4 ± 0.3 15.3 ± 0.4 88 ± 3 103 ± 4
40.0 214 ± 5 230 ± 5 93 ± 3 13.9 ± 0.3 15.6 ± 0.2 89 ± 2 104 ± 4
aPATriapine = mean peak area of triapine.
bRecoveryTriapine = [(PATriapine in plasma matrix)/(PATriapine in extracted plasma matrix)] × 100%.
cPAIS = mean peak area of IS.
dRecoveryIS = [(PAIS in plasma matrix)/(PAIS in extracted plasma matrix)] × 100%.
eIS normalized recovery = [(RecoveryTriapine)/(RecoveryIS)] × 100%.
Table 4. Accuracy and precision of plasma calibrators over
three different days (n = 6)
Sample
matrix
Nominal
[triapine]
(ng/mL)
Measured
[triapine]
(ng/mL)
SD
(ng/mL)
Precision
(CV, %)
Accuracy
(RE, %)
Pooled
human
plasma
0.250 0.25 0.01 4 0
0.500 0.50 0.03 6 0
1.00 0.98 0.08 8 2
2.50 2.5 0.1 4 1
5.00 4.9 0.4 8 2
10.0 9.8 0.5 5 2
25.0 24 2 8 4
50.0 53 2 4 6
Table 5. Intra- and inter-run accuracy and precision for
triapine in pooled human plasma
Nominal
[Triapine]
(ng/mL)
Measured
[Triapine]
(ng/mL)
SD
(ng/mL)
Precision
(CV, %)
Accuracy
(RE, %)
Intra-runa (n = 5 replicates)
0.750 0.74 0.02 3 1
7.50 8.1 0.1 1 8
40.0 40 2 5 1
400c 406 2 0.5 2
Inter-runb (n = 5 parallels)
0.750 0.72 0.01 1 4
7.50 7.0 0.3 4 7
40.0 38.2 0.9 2 4
400c 429 3 1 7
aEach datum point calculated by ﬁve replicate measure-
ments of each quality control (QC) sample.
bEach datum point calculated by ﬁve parallel measurements
from ﬁve identical QCs.
cDilution QC was measured by 10× dilution with blank
pooled human plasma.
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Stability
The stability study was conducted for triapine and the IS, and the
results were summarized in Table 6. At room temperature on the
bench-top, tiapine and the IS stock solutions were stable for up
to 24 h, whereas triapine and the IS in plasma were stable for at
least 6 h. Triapine and the IS from plasma samples were stable in
autosampler set at 4°C after sample preparation for 24 h. The re-
coveries of triapine and the IS after three freeze–thaw cycles
were 96% for the low QC and 98% for the high QC, respectively,
whereas the recovery of the IS was 92%. The studies also
showed that there was no signiﬁcant loss of triapine and the IS
during long-term (30 days) storage at 20°C.
Application of the method
The feasibility of the LC-MS/MS method was demonstrated by
the measurement of triapine concentrations in patient plasma
samples collected from a previous phase I clinical trial of pelvic
radiation, weekly cisplatin and triapine for locally advanced cer-
vical cancer (Kunos et al., 2010a, 2010b). Figure 5 showed the
triapine concentration–time proﬁle in patients’ blood samples
on days 1 and 10 by 2 h triapine infusion at a dose of
25 mg/m2 three times a week for 5 weeks. Compared with the
HPLC-UV method used in the previous work (Kunos et al.,
2010a, 2010b), the LC-MS/MS method developed not only could
produce a comparable triapine concentration–time proﬁle, but
also was capable of measuring triapine concentrations (i.e. 0 h
Table 6. Stabilities of triapine and NSC 266749 under various conditions (n = 5)a
Test conditions Temperature (°C) Recovery ± SD (%)
6 h 24 h
Triapine
Bench-top 23 Stock solution b
(1.00 × 106 ng/mL)
101 ± 1 100 ± 4
Working solution b
(1.00 × 103 ng/mL)
106 ± 3 100 ± 5
Plasma low QC c 88 ± 2 68 ± 3
Plasma high QC c 90 ± 2 61 ± 5
Autosampler 4 Plasma low QC 96 ± 1 94 ± 8
Plasma high QC 87 ± 1 83 ± 5
Three freeze–thaw cycles 20 to 23 Plasma low QC 96 ± 2
Plasma high QC 98 ± 5
Long-term (30 days) 20 Plasma low QC 86 ± 6
Plasma high QC 91 ± 5
NSC 266749b
Bench-top 23 Solution (100 ng/mL) 105 ± 2 100 ± 6
Plasma (5.00 ng/mL) 89 ± 5 84 ± 5
Autosampler 4 Plasma (5.00 ng/mL) 87 ± 3 93 ± 5
Three freeze–thaw cycles 20 to 23 Plasma (5.00 ng/mL) 92 ± 4
Long-term (30 days) 20 Plasma (5.00 ng/mL) 88 ± 7
aThe measurement of triapine used NSC 266749 (5.00 ng/mL) as IS whereas the measurement of NSC 266749 used triapine
(5.00 ng/mL) as IS.
bThe concentrations of stock solution and working solution were measured by serial dilution to 40.0 ng/mL with the dilution
solution as described in the Experimental section.
cThe concentrations of plasma low and high QCs were 0.750 and 40.0 ng/mL, respectively.
Figure 5. Mean triapine concentration time proﬁles of patients on days
1 and 10 by 2 h i.v. infusion of triapine at the dose of 25 mg/m2 three
times per week for 5 weeks.
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on day 10, and 24 h on days 1 and 10) otherwise below
the LLOQ of the HPLC-UV method (20.0 ng/mL). Therefore, the
LC-MS/MS method is better suited for the clinical study of
triapine, and has an unparalleled selectivity and LLOQ compared
with the HPLC-UV method.
Conclusion
This work has provided a detailed discussion on the develop-
ment and validation of an LC-MS/MS method for the quantita-
tion of triapine in human plasma. The method employs a
simple deproteinization protocol for sample preparation, a
reversed-phase chromatograph for analyte separation and a tan-
dem mass spectrometer for analyte quantitation. EDTA is used
as anticoagulant and metal-ion chelator to prevent the un-
wanted complexation reaction between triapine and metal-ion
interferents. This method has a linear calibration range of
0.250–50.0 ng/mL with the accuracy and precision well suited
for analysis of human plasma samples, ﬁlling the gap between
the needs of clinical trials and the less sensitive HPLC-UV
method. It is useful for clinical studies of triapine in human.
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